Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer
Erschienen in: Breast Cancer 3/2016

12.02.2016 | Special Feature

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition

verfasst von: Naruto Taira, Masami Arai, Masahiko Ikeda, Motoki Iwasaki, Hitoshi Okamura, Kiyoshi Takamatsu, Tsunehisa Nomura, Seiichiro Yamamoto, Yoshinori Ito, Hirofumi Mukai

Erschienen in: Breast Cancer | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Excerpt

In the 2015 edition of Clinical Practice Guideline of Breast Cancer, evidence grades were used as indexes for definite causal relationships, in accordance with the 2013 edition, but recommendation grades were used for clinical questions (CQs) on prevention and risk assessment. The major revisions to the 2015 edition were as follows.
  • In the section entitled “Risk factors for breast cancer” in the 2013 edition, a decrease in breast cancer risk due to obesity in premenopausal women was determined to be probable. However, a large-scale pooled analysis in Japanese women reported in 2014 showed a significant increase in breast cancer risk in premenopausal women with a high body mass index. Due to this report, the description has been changed to “obesity may increase the risk of breast cancer in premenopausal women” in the 2015 edition. Body mass in Asian women might have opposite effects on breast cancer compared to that in Western women.
  • In the section entitled “Risk assessment and chemoprevention”, 2 CQs have been added on risk assessment using information on single-nucleotide polymorphisms, and on breast density and the risk of breast cancer.
…
Literatur
1.
Kawamura T, Sobue T. Comparison of breast cancer mortality in five countries: France, Italy, Japan, the UK and the USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol. 2005;35:758–9.CrossRefPubMed
2.
Katanoda K, Qiu D. Comparison of time trends in female breast cancer incidence (1973 1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents, Vols IV VIII. Jpn J Clin Oncol. 2007;37:638–9.CrossRefPubMed
3.
World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer:a global perspective. Washington DC: AICR; 2007.
4.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.CrossRefPubMed
5.
Wada K, Nagata C, Tamakoshi A, Matsuo K, Oze I, Wakai K, et al. Body mass index and breast cancer risk in Japan: a pooled analysis of eight population-based cohort studies. Ann Oncol. 2014;25:519–24.CrossRefPubMed
6.
Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V, Million Women Study collaborators. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12:785–94.CrossRefPubMedPubMedCentral
7.
White KK, Park SY, Kolonel LN, Henderson BE, Wilkens LR. Body size and breast cancer risk: the Multiethnic Cohort. Int J Cancer. 2012;131:E705–16.CrossRefPubMedPubMedCentral
8.
Sung J, Song YM, Lawlor DA, Smith GD, Ebrahim S. Height and site-specific cancer risk: a cohort study of a Korean adult population. Am J Epidemiol. 2009;170:53–64.CrossRefPubMed
9.
Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15:36–47.PubMed
10.
Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, Nishino Y, et al. Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi Cohort Study. Cancer Causes Control. 2010;21:135–45.CrossRefPubMed
11.
Tamakoshi K, Yatsuya H, Wakai K, Suzuki S, Nishio K, Lin Y, JACC Study Group, et al. Impact of menstrual and reproductive factors on breast cancer risk in Japan: results of the JACC study. Cancer Sci. 2005;96:57–62.CrossRefPubMed
12.
Iwasaki M, Otani T, Inoue M, Sasazuki S, Tsugane S, Japan Public Health Center-based Prospective Study Group. Role and impact of menstrual and reproductive factors on breast cancer risk in Japan. Eur J Cancer Prev. 2007;16:116–23.CrossRefPubMed
13.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360:187–95.CrossRef
14.
Tokunaga M, Land CE, Yamamoto T, Asano M, Tokuoka S, Ezaki H, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat Res. 1987;112:243–72.CrossRefPubMed
15.
Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S. Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res. 1994;138:209–23.CrossRefPubMed
16.
Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217–23.CrossRefPubMedPubMedCentral
17.
Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152:444–55.CrossRefPubMedPubMedCentral
18.
Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125–9.CrossRefPubMed
19.
Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:29–32.PubMed
20.
Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331:10–5.CrossRefPubMed
21.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146–51.CrossRefPubMed
22.
Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229–37.CrossRefPubMed
23.
Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, et al. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control. 2010;21:821–8.CrossRefPubMedPubMedCentral
24.
Ma L, Boyd NF. Atypical hyperplasia and breast cancer risk: a critique. Cancer Causes Control. 1992;3:517–25.CrossRefPubMed
25.
Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71:800–9.CrossRefPubMed
26.
Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, WHI Investigators, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304:1684–92.CrossRefPubMed
27.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3 N cohort study. Breast Cancer Res Treat. 2008;107:103–11.CrossRefPubMedPubMedCentral
28.
Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13:476–86.CrossRefPubMedPubMedCentral
29.
Saeki T, Sano M, Komoike Y, Sonoo H, Honjyo H, Ochiai K, et al. No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan. Int J Clin Oncol. 2008;13:8–11.CrossRefPubMed
30.
Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, Nishino Y, et al. Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi Cohort Study. Cancer Causes Control. 2010;21:135–45.CrossRefPubMed
31.
Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, et al. Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat. 2014;144:479–502.CrossRefPubMed
32.
Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. AJR Am J Roentgenol. 1987;148:1087–92.CrossRefPubMed
33.
McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a metaanalysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1159–69.CrossRefPubMed
34.
Maskarinec G, Pagano I, Lurie G, Wilkens LR, Kolonel LN. Mammographic density and breast cancer risk: the multiethnic cohort study. Am J Epidemiol. 2005;162:743–52.CrossRefPubMed
35.
Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan, et al. Alcohol drinking and breast cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2007;37:568–74.CrossRefPubMed
36.
Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, Japan Public Health Center-Based Prospective Study Group, et al. Alcohol consumption-associated breast cancer incidence and potential effect modifiers: the Japan Public Health Center-based Prospective Study. Int J Cancer. 2010;127:685–95.CrossRefPubMed
37.
Kawai M, Minami Y, Kakizaki M, Kakugawa Y, Nishino Y, Fukao A, et al. Alcohol consumption and breast cancer risk in Japanese women: the Miyagi Cohort study. Breast Cancer Res Treat. 2011;128:817–25.CrossRefPubMed
38.
Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan, et al. Tobacco smoking and breast cancer risk:an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol. 2006;36:387–94.CrossRefPubMed
39.
Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol. 2007;8:1088–100.CrossRefPubMed
40.
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141–51.CrossRefPubMedCentral
41.
Nagata C, Hu YH, Shimizu H. Effects of menstrual and reproductive factors on the risk of breast cancer:meta-analysis of the case-control studies in Japan. Jpn J Cancer Res. 1995;86:910–5.CrossRefPubMed
42.
Suzuki S, Kojima M, Tokudome S, Mori M, Sakauchi F, Fujino Y, Japan Collaborative Cohort Study Group, et al. Effect of physical activity on breast cancer risk: findings of the Japan collaborative cohort study. Cancer Epidemiol Biomarkers Prev. 2008;17:3396–401.CrossRefPubMed
43.
Suzuki R, Iwasaki M, Yamamoto S, Inoue M, Sasazuki S, Sawada N, Japan Public Health Center-based Prospective Study Group, et al. Leisure-time physical activity and breast cancer risk defined by estrogen and progesterone receptor status: the Japan Public Health Center-based Prospective Study. Prev Med. 2011;52:227–33.PubMed
44.
Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856–62.CrossRefPubMed
45.
Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104:1499–507.CrossRefPubMed
46.
Dong JY, Zhang L, He K, Qin LQ. Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies. Breast Cancer Res Treat. 2011;127:23–31.CrossRefPubMed
47.
Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S, Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003;95:906–13.CrossRefPubMed
48.
Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Japan Public Health Center-based prospective study group, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol. 2008;26:1677–83.CrossRefPubMed
49.
Nishio K, Niwa Y, Toyoshima H, Tamakoshi K, Kondo T, Yatsuya H, et al. Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study. Cancer Causes Control. 2007;18:801–8.CrossRefPubMed
50.
Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 2006;98:459–71.CrossRefPubMed
51.
Nagata C, Mizoue T, Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, et al. Soy intake and breast cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44:282–95.CrossRefPubMed
52.
Bosetti C, Scotti L, Negri E, Talamini R, Levi F, Franceschi S, et al. Benign ovarian cysts and breast cancer risk. Int J Cancer. 2006;119:1679–82.CrossRefPubMed
53.
Knight JA, John EM, Milne RL, Dite GS, Balbuena R, Shi EJ, et al. An inverse association between ovarian cysts and breast cancer in the breast cancer family registry. Int J Cancer. 2006;118:197–202.CrossRefPubMed
54.
Knight JA, Lesosky M, Blackmore KM, Voigt LF, Holt VL, Bernstein L, et al. Ovarian cysts and breast cancer: results from the Women’s Contraceptive and Reproductive Experiences Study. Breast Cancer Res Treat. 2008;109:157–64.CrossRefPubMed
55.
Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. Br J Cancer. 1997;75:1699–703.CrossRefPubMedPubMedCentral
56.
Miller MD, Marty MA, Broadwin R, Johnson KC, Salmon AG, Winder B, California Environmental Protection Agency, et al. The association between exposure to environmental tobacco smoke and breast cancer:a review by the California Environmental Protection Agency. Prev Med. 2007;44:93–106.CrossRefPubMed
57.
Pirie K, Beral V, Peto R, Roddam A, Reeves G, Green J. Million Women Study Collaborators. Int J Epidemiol. 2008;37:1069–79.CrossRefPubMed
58.
Dossus L, Boutron-Ruault MC, Kaaks R, Gram IT, Vilier A, Fervers B, et al. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer. 2014;134:1871–88.CrossRefPubMed
59.
Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635–48.CrossRefPubMedPubMedCentral
60.
Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81:1290–302.CrossRefPubMed
61.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.CrossRef
62.
Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst. 2008;100:1037–41.CrossRefPubMedPubMedCentral
63.
Sueta A, Ito H, Kawase T, Hirose K, Hosono S, Yatabe Y, et al. A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat. 2012;132:711–21.CrossRefPubMed
64.
Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013;158(8):604–14.CrossRefPubMed
65.
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, NCIC CTG MAP.3 Study Investigators, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.CrossRefPubMed
66.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041–8.CrossRefPubMed
67.
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.CrossRefPubMedPubMedCentral
68.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. ver1. 2013.
69.
Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, American Cancer Society Breast Cancer Advisory Group, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89.CrossRefPubMed
70.
Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28:1450–7.CrossRefPubMed
71.
Pijep A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, GENEPSO; EMBRACE; HEBON, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660.CrossRef
72.
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62.CrossRefPubMed
73.
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–64.CrossRefPubMed
74.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.CrossRefPubMedPubMedCentral
75.
van Sprundel TC1, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutatuion carriers. Br J Cancer 2005; 93: 287–92.
76.
Kaas R1, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg 2010; 251: 488–92.
77.
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.CrossRefPubMedPubMedCentral
78.
Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135–42.CrossRefPubMed
79.
Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136:668–77.PubMed
80.
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251–6.CrossRefPubMed
81.
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876–81.CrossRefPubMed
82.
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.CrossRefPubMedPubMedCentral
83.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.CrossRefPubMedPubMedCentral
84.
Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer. 2007;96:1335–42.PubMedPubMedCentral
85.
Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627–35.CrossRefPubMed
86.
Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23:1370–8.CrossRefPubMed
87.
Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990;8:1327–34.PubMed
88.
Zhong S, Jiang T, Ma T, Zhang X, Tang J, Chen W, et al. Association between physical activity and mortality in breast cancer: a meta-analysis of cohort studies. Eur J Epidemiol. 2014;29:391–404.CrossRefPubMed
89.
Pierce JP, Patterson RE, Senger CM, Flatt SW, Caan BJ, Natarajan L, et al. Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. J Natl Cancer Inst. 2014; 106: djt359.
90.
Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2011;125:315–23.CrossRefPubMed
91.
Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012;96:123–32.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition
verfasst von
Naruto Taira
Masami Arai
Masahiko Ikeda
Motoki Iwasaki
Hitoshi Okamura
Kiyoshi Takamatsu
Tsunehisa Nomura
Seiichiro Yamamoto
Yoshinori Ito
Hirofumi Mukai
Publikationsdatum
12.02.2016
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 3/2016
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0673-8

Weitere Artikel der Ausgabe 3/2016

Breast Cancer 3/2016 Zur Ausgabe

Special Feature

The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition

Original Article

Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ

Special Feature

The Japanese Breast Cancer Society clinical practice guidelines for screening and imaging diagnosis of breast cancer, 2015 edition

Original Article

Flap adhesion and effect on postoperative complication rates using Tissuglu® in mastectomy patients

Original Article

Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types

Special Feature

The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2015 edition

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen